<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="app1table6" position="float"><object-id pub-id-type="doi">10.7554/eLife.37110.022</object-id><label>Appendix 1&#8212;table 6.</label><caption><title>Summary of all the association tests for GRS.</title><p>All GRS related tests from the main text. The notation of MED12mut&#160;+&#160;and MED12mut- refer to the numbers of <italic>MED12</italic>-mutation-positive and -negative tumors, respectively. The tests include Wilcoxon rank-sum and models for linear and negative binomial (NB) regression (variable&#160;~GRS). The P values were adjusted for FWER with the Holm-Bonferroni method (Q). Significant associations (Q&#160;&lt;&#160;0.05) are shown bolded. Note that population association tests include only the female controls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>GRS <sup>*</sup></th><th>Cohort</th><th>Variable</th><th>Test</th><th>N cases</th><th>N controls</th><th>Rate ratio</th><th>P</th><th>Q</th></tr></thead><tbody><tr><td>&#8195;Stage 1</td><td>Helsinki</td><td>UL phenotype</td><td>Rank-sum <sup>(one-tailed)</sup></td><td>457</td><td>8899</td><td>-</td><td>8.3e-10</td><td><bold>1.1e-08</bold></td></tr><tr><td>&#8195;Stage 2</td><td>NFBC</td><td>UL phenotype</td><td>Rank-sum <sup>(one-tailed)</sup></td><td>459</td><td>2351</td><td>-</td><td>1.1e-05</td><td><bold>1.1e-04</bold></td></tr><tr><td>&#8195;Stage 2</td><td>Helsinki</td><td>Total number of ULs</td><td>NB</td><td>457</td><td>-</td><td>1.25</td><td>0.00105</td><td><bold>0.0032</bold></td></tr><tr><td>&#8195;Stage 2</td><td>Helsinki</td><td>Age at hysterectomy</td><td>Linear</td><td>392</td><td>-</td><td>0.50</td><td>0.48</td><td>0.48</td></tr><tr><td>&#8195;Stage 2</td><td>Helsinki</td><td>Number of MED12mut+</td><td>NB</td><td>457</td><td>-</td><td>1.43</td><td>3.2e-04</td><td><bold>0.002</bold></td></tr><tr><td>&#8195;Stage 2</td><td>Helsinki</td><td>Number of MED12mut-</td><td>NB</td><td>457</td><td>-</td><td>0.79</td><td>0.0266</td><td>0.053</td></tr><tr><td>&#8195;Stage 2</td><td>Helsinki</td><td>One-or-more MED12mut+</td><td>Rank-sum</td><td>334</td><td>123</td><td>-</td><td>5.3e-04</td><td><bold>0.0026</bold></td></tr><tr><td>&#8195;Stage 2</td><td>Helsinki</td><td>All MED12mut+</td><td>Rank-sum</td><td>221</td><td>123</td><td>-</td><td>7.9e-04</td><td><bold>0.0032</bold></td></tr><tr><td>&#8195;Stage 2</td><td>African <sup>#</sup></td><td>UL phenotype</td><td>Rank-sum <sup>(one-tailed)</sup></td><td>296</td><td>1256</td><td>-</td><td>1.3e-05</td><td><bold>1.2e-04</bold></td></tr><tr><td>&#8195;Stage 2</td><td>Caribbean<sup>#</sup></td><td>UL phenotype</td><td>Rank-sum <sup>(one-tailed)</sup></td><td>668</td><td>2041</td><td>-</td><td>6.7e-05</td><td><bold>5.4e-04</bold></td></tr><tr><td>&#8195;Stage 2</td><td>Irish <sup>#</sup></td><td>UL phenotype</td><td>Rank-sum <sup>(one-tailed)</sup></td><td>398</td><td>6208</td><td>-</td><td>8.3e-06</td><td><bold>9.1e-05</bold></td></tr><tr><td>&#8195;Stage 2</td><td>Indian <sup>#</sup></td><td>UL phenotype</td><td>Rank-sum <sup>(one-tailed)</sup></td><td>203</td><td>2567</td><td>-</td><td>2.9e-04</td><td><bold>0.0020</bold></td></tr><tr><td valign="top">&#8195;Stage 2</td><td valign="top">Other white <sup>#</sup></td><td valign="top">UL phenotype</td><td valign="top">Rank-sum <sup>(one-tailed)</sup></td><td valign="top">647</td><td valign="top">8982</td><td valign="top">-</td><td valign="top">6.9e-09</td><td valign="top"><bold>8.3e-08</bold></td></tr></tbody></table><table-wrap-foot><fn><p><sup>*</sup>Based either on stage 1 (UKBB GWAS) or stage 2 (meta-analysis of UKBB and Helsinki)</p><p><sup>#</sup> An independent subset of UKBB data (stratified based on self-reported UKBB annotation).</p></fn></table-wrap-foot></table-wrap>